21 Stocks Moving in Wednesday's Pre-Market Session
Benzinga
Published Jun 22, 2022 11:54
Updated Jun 22, 2022 12:40
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers
- Codex DNA, Inc. (NASDAQ: DNAY) rose 64.5% to $3.52 in pre-market trading after declining 10% on Tuesday.
- Quotient Limited (NASDAQ: QTNT) rose 57.8% to $0.5896 in pre-market trading. Quotient said it expects to report reagent business generated product sales of $9.8m in the fourth quarter of Fiscal 2022. The company also sees FY22 revenue of $38.5 million.
- U.S. Well Services, Inc. (NASDAQ: USWS) rose 37.7% to $0.9898 in pre-market trading after ProFrac Holding Corp. (NASDAQ: PFHC) announced plans to acquire the company for $1.21 per share in an all-stock deal.
- Precision BioSciences, Inc. (NASDAQ: DTIL) shares rose 33.8% to $1.86 in pre-market trading as the company reported a $50 million offering of common stock and announced in vivo gene editing collaboration with Novartis to develop potentially curative treatment for disorders including sickle cell disease.
- Revlon, Inc. (NYSE: REV) rose 26.9% to $7.69 in pre-market trading on continued volatility following the company's recent bankruptcy filing and approval of a $375 million loan. The stock has also been circulated as a short squeeze candidate.
- Regis Corporation (NYSE: RGS) rose 12.1% to $0.74 in pre-market trading. Regis recently announced a partnership with Zenoti.
- Clovis Oncology, Inc. (NASDAQ: CLVS) shares rose 11% to $1.82 in pre-market trading after jumping 39% on Tuesday. Clovis Oncology, last week, announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).
- La-Z-Boy Incorporated (NYSE: LZB) rose 7.7% to $24.50 in pre-market trading after the company reported upbeat results for its fourth quarter and issued strong sales forecast for the first quarter.
- Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 6.3% to $4.37 in pre-market trading after declining 7% on Tuesday. Comera Life Sciences was recently granted a US patent titled 'Excipient compounds for protein processing.'
Losers
- Micro Focus International (LON:MCRO) plc (NYSE: MFGP) fell 14.4% to $3.69 in pre-market trading.
- Almaden Minerals Ltd. (NYSE: AAU) fell 11.4% to $0.2136 in pre-market trading.
- AgEagle Aerial Systems, Inc. (NYSE: UAVS) fell 10.5% to $0.69 in pre-market trading. AgEagle Aerial Systems shares jumped 33% on Tuesday after the company announced the European Union Aviation Safety Agency issued a Design Verification Report (DVR) establishing that the eBee X meets Ground Risk Class M2 mitigation qualifications.
- I-Mab (NASDAQ: IMAB) fell 10.2% to $10.67 in pre-market trading after jumping around 8% on Tuesday.
- Borr Drilling Limited (NYSE: BORR) shares fell 10.2% to $5.47 in pre-market trading following a 10% surge on Tuesday.
- Houston American Energy Corp. (NYSE: HUSA) fell 8.8% to $4.76 in pre-market trading after declining around 5% on Tuesday.
- Motus GI Holdings, Inc. (NASDAQ: MOTS) shares fell 8.6% to $0.2410 in pre-market trading. Motus GI Holdings, last month, announced data from an investigator initiated EU study on the Pure-Vu system at Digestive Disease Week 2022.
- Centennial Resource Development, Inc. (NASDAQ: CDEV) fell 7.8% to $6.85 in pre-market trading.
- MorphoSys AG (NASDAQ: MOR) fell 7.8% to $4.87 in pre-market trading after gaining around 7% on Tuesday. I-Mab’s Partner MorphoSys recently announced new license agreements for Felzartamab and TJ210.
- Ovintiv Inc. (NYSE: OVV) shares fell 7.1% to $46.98 in pre-market trading after gaining 8% on Tuesday.
- Sana Biotechnology, Inc. (NASDAQ: SANA) shares fell 6.1% to $5.39 in pre-market trading after climbing more than 11% on Tuesday.
- Valneva SE (NASDAQ: VALN) fell 5.9% to $24.93 in pre-market trading. Valneva shares jumped 93% on Tuesday after the company and Pfizer (NYSE:PFE) announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15.
Get The App
Read at Benzinga
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.